FILE PHOTO: A handout photo shows an employee demonstrating vials with "Gam-COVID-Vac" vaccine against the coronavirus disease (COVID-19), developed by the Gamaleya National Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), during its production at Binnopharm pharmaceutical company in Zelenograd near Moscow, Russia August 7, 2020. The Russian Direct Investment Fund (RDIF)/Andrey Rudakov/Handout via REUTERS
MOSCOW (Reuters) - Russia's "Sputnik-V" COVID-19 vaccine produced an antibody response in all participants in early-stage trials, according to results published on Friday by The Lancet medical journal that were hailed by Moscow as an answer to its critics.
The results of the two trials, conducted in June-July this year and involving 76 participants, showed 100% of participants developing antibodies to the new coronavirus and no serious side effects, The Lancet said.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
